Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

C. Klonoff, David; B. Buse, John; L. Nielsen, Loretta; Guan, Xuesong; L. Bowlus, Christopher; H. Holcombe, John; Wintle, Matthew; Maggs, David

doi:10.1185/030079908x253870

Public

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Published in Current Medical Research and Opinion • Dec 3, 2007

Authors:

David C. Klonoff

John B. Buse

Loretta L. Nielsen

Abstract

BACKGROUND: Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A(1c) (A1C) and weight in clinical trials. The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic m...

Subject

Exenatide

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!